
Claims:










1. An ophthalmic composition, comprising: from 0.05 w/v% to 5 w/v% of galactomannan polymer; a cis- diol and 0.5 w/v% to 10 w/v% of a hydrophilic copolymer which comprises (a) arylborono-containing repeating units each having a boronic acid, (b) repeating units of at least one phosphorylcholine-containing vinylic monomer, and (c) acrylic monomeric units of at least one acrylic monomer having 3 to 16 carbon atoms, the composition comprises less than 0.1 %W/V of a borate, wherein each type of arylborono-containing repeating units is derived from an arylborono-containing vinylic monomer.

2. The ophthalmic composition of claim 1, wherein said at least one arylborono-containing vinylic monomer is a vinylic monomer of formula (II)



(II)

in which:

R_1 is H, NO_2, F, Cl, or CF_3; Q is a monovalent radical of , , , , , , , or ; L is a direct bond, a C_1-C_4 alkylene divalent radical, a divalent radical of , , , or  in which Y_1 is CH(OH) or a C_1-C_4 alkylene divalent radical, Y_2 is a C_1-C_4 alkylene divalent radical, and R^o is H or a C_1-C_4 alkyl.

3. The ophthalmic composition of claim 2, wherein said at least one arylborono-containing vinylic monomer is selected from the group consisting of 3-vinylphenylboronic acid, 4-vinylboronic acid, 3-(meth)acrylamidophenylboronic acid, 4-(meth)acrylamidophenylboronic acid, and combinations thereof.

4. The ophthalmic composition of claim 1, wherein the phosphorylcholine-containing vinylic monomer is selected from the group consisting of (meth)acryloyloxyethyl phosphorylcholine, (meth)acryloyloxypropyl phosphorylcholine, 4-((meth)acryloyloxy)butyl-2'-(trimethylammonio)ethylphosphate, 2-[(meth)acryloylamino]ethyl-2'-(trimethylammonio)-ethylphosphate, 3-[(meth)acryloylamino]propyl-2'-(trimethylammonio)ethylphosphate, 4-[(meth)acryloylamino]butyl-2'-(trimethylammonio)ethylphosphate, 5-((meth)acryloyloxy)pentyl-2'-(trimethylammonio)ethyl phosphate, 6-((meth)acryloyloxy)hexyl-2'-(trimethylammonio)-ethylphosphate, 2-((meth)acryloyloxy)ethyl-2'-(triethylammonio)ethylphosphate, 2-((meth)acryloyloxy)ethyl-2'-

(tripropylammonio)ethylphosphate, 2-((meth)acryloyloxy)ethyl-2'-(tributylammonio)ethyl phosphate, 2-((meth)acryloyloxy)propyl-2'-(trimethylammonio)-ethylphosphate, 2-((meth)acryloyloxy)butyl-2'-(trimethylammonio)ethylphosphate, 2-((meth)acryloyloxy)pentyl-2'-(trimethylammonio)ethylphosphate, 2-((meth)acryloyloxy)hexyl-2'-(trimethylammonio)ethyl phosphate, 2-(vinyloxy)ethyl-2'-(trimethylammonio)ethylphosphate, 2-(allyloxy)ethyl-2'-(trimethylammonio)ethylphosphate, 2-(vinyloxycarbonyl)ethyl-2'-(trimethylammonio)ethyl phosphate, 2-(allyloxycarbonyl)ethyl-2'-(trimethylammonio)-ethylphosphate, 2-(vinylcarbonylamino)ethyl-2'-(trimethylammonio)ethylphosphate, 2-(allyloxycarbonylamino)ethyl-2'-(trimethylammonio)ethyl phosphate, 2-(butenoyloxy)ethyl-2'-(trimethylammonio)ethylphosphate, and combinations thereof.

5. The ophthalmic composition of claim 1, wherein said at least one at least one acrylic monomer is selected from the group consisting of a C1–C12 alkyl (meth)acrylate, a hydroxy-substituted C2–C12 alkyl (meth)acrylate, a carboxy-substituted C2–C12 alkyl (meth)acrylate, an NH2-substituted C2–C12 alkyl (meth)acrylate, a methylamino-substituted C2–C12 alkyl (meth)acrylate, a dimethylamino-substituted C2–C12 alkyl (meth)acrylate, an ethylamino-substituted C2–C10 alkyl (meth)acrylate, a diethylamino-substituted C2–C8 alkyl (meth)acrylate, a C2–C12 alkyl (meth)acrylamide, a hydroxy-substituted C2–C12 alkyl (meth)acrylamide, a carboxy-substituted C2–C12 alkyl (meth)acrylaide, an NH2-substituted C2–C12 alkyl (meth)acrylamide, a methylamino-substituted C2–C12 alkyl (meth)acrylamide, a dimethylamino-substituted C2–C12 alkyl (meth)acrylamide, an ethylamino-substituted C2–C10 alkyl (meth)acrylamide, a diethylamino-substituted C2–C8 alkyl (meth)acrylamide, ethylene glycol (meth)acrylate, di(ethylene glycol) (meth)acrylate, tri(ethylene glycol) (meth)acrylate, tetra(ethylene glycol) (meth)acrylate, ethylene glycol methyl ether (meth)acrylate, di(ethylene glycol) methyl ether (meth)acrylate, tri(ethylene glycol) methyl ether (meth)acrylate, tetra(ethylene glycol) methyl ether (meth)acrylate, and combinations thereof. (meth)acrylamide, N,N-dimethyl (meth)acrylamide, N-vinylpyrroli¬done (NVP), N-vinyl formamide, N-vinyl acetamide, N-vinyl isopropylamide, N-vinyl-N-methyl acetamide, N,N-dimethylaminoethyl (meth)acrylate, N,N-dimethylaminopropyl (meth)acrylamide, N-2-hydroxylethyl (meth)acrylamide, N,N-bis(hydroxyethyl) (meth)acrylamide, N-3-hydroxypropyl (meth)acrylamide, N-2-hydroxypropyl (meth)acrylamide, N-2,3-dihydroxypropyl (meth)acrylamide, N-tris(hydroxymethyl)methyl (meth)acrylamide, 2-hydroxyethyl (meth)acrylate, 3-hydroxypropyl (meth)acrylate, 2-hydroxypropyl (meth)acrylate, glycerol methacrylate (GMA), di(ethylene glycol) (meth)acrylate, tri(ethylene glycol) (meth)acrylate, tetra(ethylene glycol) (meth)acrylate, poly(ethylene glycol) (meth)acrylate having a number average molecular weight of up to 1500, poly(ethylene glycol)ethyl (meth)acrylamide having a number average molecular weight of up to 1500, N-methyl-3-methylene-2-pyrrolidone, 1-

ethyl-3-methylene-2-pyrrolidone, 1-methyl-5-methylene-2-pyrrolidone, 1-ethyl-5-methylene-2-pyrrolidone, 5-methyl-3-methylene-2-pyrrolidone, 5-ethyl-3-methylene-2-pyrrolidone, ethylene glycol methyl ether (meth)acrylate, di(ethylene glycol) methyl ether (meth)acrylate, tri(ethylene glycol) methyl ether (meth)acrylate, tetra(ethylene glycol) methyl ether (meth)acrylate, C1-C4-alkoxy poly(ethylene glycol) (meth)acrylate having a weight average molecular weight of up to 1500, methoxy-poly(ethylene glycol)ethyl (meth)acrylamide having a number average molecular weight of up to 1500, allyl alcohol, vinyl alcohol, and combinations thereof.

6. The ophthalmic composition of claim 1, wherein the hydrophilic copolymer comprises (a) from 1% to 20% by mole of the arylborono-containing repeating units, (b) from 60% to 98% by mole of repeating units of at least one phosphorylcholine-containing vinylic monomer, and (c) from 1% by mole to 20% by mole of acrylic monomeric units of at least one acrylic monomer having 3 to 16 carbon atoms, provided that the sum of the mole percentages of components (a), (b) and (c) and other components not listed above is 100%.

7. The ophthalmic composition according to any one of claims 1 to 6, wherein the phosphate-modified galactomannan polymer is present in the ophthalmic composition at a concentration of from 0.05 to 3 w/v%.

8. The ophthalmic composition according to any one of claims 1 to 6, wherein the phosphate-modified galactomannan polymer is present in the ophthalmic composition at a concentration of from 0.1 to 1.0 w/v%.

9. The ophthalmic composition according to any one of claims 1 to 6, wherein the phosphate-modified galactomannan polymer is present in the ophthalmic composition at a concentration of from 0.15 to 0.25 w/v%.

10. The ophthalmic composition of claim 12, wherein the composition has a pH value between 6.5 to 8.5.

11. The ophthalmic composition of claim 1, wherein the ophthalmic composition comprises at least one cis-diol compound at a concentration that reduces (inhibits) cross-linking of the galactomannan polymer by the hydrophilic copolymer.

12. The ophthalmic composition of claim 11, wherein the cis-diol compound is present at a concentration of from 0.5 to 5.0 w/v%.

13. The ophthalmic composition according to any one of claims 11 to 12, wherein the cis-diol compound is sorbitol, mannitol, propylene glycol, or combinations thereof.

14. The ophthalmic composition according to any one of claims 1 to 13, wherein the ophthalmic composition comprises at least one demulcent selected from the group consisting of glycerin, polyvinyl pyrrolidone, polyethylene oxide, polyethylene glycol, polyethyleoxide-polybutyleneoxide block copolymer, polyethyleneoxide-polypropyleneoxide block copolymer, propylene glycol, polyacrylic acid, and combinations thereof.

15. The ophthalmic composition of claim 14, wherein said at least one demulcent demulcent is propylene glycol and polyethylene glycol 400.